# 5-aza-4'-Thio-2'-Deoxycytidine (Aza-TdC) in People With Advanced Solid Tumors

> **NCT03366116** · PHASE1 · RECRUITING · sponsor: **National Cancer Institute (NCI)** · enrollment: 65 (estimated)

## Conditions studied

- Neoplasms
- Solid Tumors

## Interventions

- **DRUG:** aza-TdC

## Key facts

- **NCT ID:** NCT03366116
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2018-11-05
- **Primary completion:** 2026-09-30
- **Final completion:** 2026-09-30
- **Target enrollment:** 65 (ESTIMATED)
- **Last updated:** 2026-05-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03366116

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03366116, "5-aza-4'-Thio-2'-Deoxycytidine (Aza-TdC) in People With Advanced Solid Tumors". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03366116. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*